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ABSTRACT  34 
The recent understanding of plasma cell (PC) biology has been obtained from murine 35 
models mainly. The current concept is that plasmablasts home to the BM and further 36 
differentiate into long-lived PCs (LLPCs). These LLPCs survive for months in contact 37 
with a complex niche comprising stromal cells (SCs) and hematopoietic cells both 38 
producing recruitment and survival factors. Using a multi-step culture system, we 39 
show here the possibility to differentiate human memory B cells into LLPCs surviving 40 
for at least 4 months in vitro and producing immunoglobulins continuously. A 41 
remarkable feature is that IL-6 is mandatory to generate LLPCs in vitro together with 42 
either APRIL or soluble factors produced by SCs, unrelated to APRIL/BAFF, SDF-1, 43 
or IGF-1. These LLPCs are out of the cell cycle, express highly PC transcription 44 
factors and surface markers.  45 
This model shows a remarkable robustness of human LLPCs, which can survive and 46 
produce highly immunoglobulins for months in vitro without contact with niche cells, 47 
providing the presence of a minimal cocktail of growth factors and nutrients. This 48 
model should be useful to understand further normal PC biology and its deregulation 49 
in premalignant or malignant PC disorders. 50 
 51 
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INTRODUCTION 53 
Mature memory plasma cells (PCs), termed long lived plasma cells (LLPCs), are 54 
located in the bone marrow (BM) or mucosa and may survive for years, insuring long-55 
term immune memory.1 LLPCs are rare cells (0.25 % of BM cells)2,3 making their 56 
study difficult in humans. Recent knowledge about their generation and maintenance 57 
was obtained with murine models mainly. After selection of antigen (Ag) specific B 58 
cells in the germinal center, involving mutations in immunoglobulin (Ig) variable 59 
genes and isotype switching, centrocytes differentiate into memory B cells (MBCs) or 60 
plasmablasts (PBs). These PBs migrate to medullary cords, exit into the lymph 61 
through a sphingosine phosphate gradient and get to the peripheral blood.4 62 
Circulating PBs have to find a specific niche in the BM or mucosa that will provide 63 
them with the factors to survive and fully differentiate. The restricted number of 64 
suitable PC niches is supposed to be the main limiting factor explaining LLPC rarity.4 65 
In mice, Tokoyoda et al. have reported the PC niche to be a VCAM1+ SDF-1+ stromal 66 
cell that could be shared by hematopoietic progenitors and pre-pro B cells.5 Several 67 
hematopoietic cell subsets have been described to be involve in PC retention, 68 
maturation, and maintenance in the BM, including macrophages, eosinophils, and 69 
megakaryocytes.6 At least 3 growth factors and chemokines, produced by the 70 
exquisite PC niche, are recognized to control PC survival: SDF-1, APRIL/BAFF, and 71 
IL-6.4 SDF-1, produced by SCs is essential to recruit mouse PBs into the BM.5,7 72 
BAFF and APRIL are produced by hematopoietic cells and are critical to support PC 73 
survival.6 BAFF binds to 3 receptors, BAFF receptor, BCMA and TACI, whereas 74 
APRIL binds to BCMA and TACI in vivo.8 Although both APRIL and BAFF can 75 
support murine LLPC survival,9 APRIL appears to be more efficient than BAFF to 76 
promote LLPC survival, at least in mice. First, APRIL binds to BCMA with a higher 77 
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affinity than BAFF,8 and BCMA is highly expressed in PCs.10 Secondly, APRIL and 78 
its receptor TACI bind to heparan sulfate chains, in particular to the proteoglycan 79 
syndecan-1,11,12 which is a hallmark of mature PCs.13 Thirdly, the long-term survival 80 
of transferred LLPCs is impaired in APRIL-/- mice, but unaffected in BAFF-/- ones.14 81 
IL-6, produced by SCs or dendritic cells, is essential for the generation of PBs, and 82 
its role in supporting LLPC survival is controversial in mice. The generation of Ag-83 
specific PCs is dramatically decreased in IL-6-/- mice15 and the ability of BM SCs to 84 
support the survival of purified BM LLPCs in vitro is inhibited by an anti-IL-6 85 
monoclonal antibody (mAb) or lost using IL-6-/- mice SCs.16,17 Similarly, the survival of 86 
LLPCs in the culture of intestine biopsies is impaired by an anti-IL-6 mAb or an 87 
APRIL/BAFF inhibitor.18 But the persistence of LLPCs transferred into IL-6-/- mice is 88 
unaffected.14 89 
In humans, the factors that promote the differentiation of PBs into LLPCs are poorly 90 
identified in vivo, due to the rarity of bone marrow PCs (BMPCs) and the ethical 91 
difficulty to harvest the BM. The majority of the studies dealing with PC survival and 92 
growth were done with malignant PCs.19,20 Using in vitro models of differentiation of B 93 
cells into PCs, we and others have shown that in vitro generated PCs are early PCs 94 
with a phenotype close to that of circulating PBs and PCs in healthy individuals.10,21,22 95 
These in vitro generated PCs expressed highly CD38 and CD31 and lack B cell 96 
antigens (CD20, CD22, CD24) except CD19. They express CD138 but at lower level 97 
than BMPCs, they express CD62L unlike BMPCs, and fail to express CD9, VCAM1, 98 
and CCR2.10 Recent studies have proposed a role for osteoclasts23 or SCs to support 99 
human PC survival in vitro.24 In this last study, blood B cells could be differentiated 100 
into Ig-secreting LLPCs in contact with soluble factors produced by a mouse SC line. 101 
However, the molecular mechanisms of this supportive activity remain unknown.24 102 
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In the current study, we show that IL-6 is mandatory for the in vitro survival of LLPCs 103 
in combination with either APRIL or BAFF or APRIL/BAFF-unrelated SC soluble 104 
factors. These LLPCs are non-cell cycling, survive for months in vitro, while 105 
producing Igs continuously.   106 
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MATERIALS AND METHODS  107 
Reagents 108 
Human recombinant IL-2, TACI-Fc, and APRIL were purchased from R&D Systems 109 
(Minneapolis, MN), IFN-α (IntronA) from Merck Canada Inc. (Kirckland, Canada), IL-6 110 
and IL-15 from AbCys SA (Paris, France), BAFF, SDF-1α, IGF-1, and IL-10, from 111 
Peprotech (Rocky Hill, NJ, USA), the B-E8 anti-IL-6 mouse mAb from Diaclone 112 
(Besançon, France), the SDF-1 inhibitor AMD3100 from Sigma (Sigma-Aldrich, St 113 
Louis, MO), the IGF-1R inhibitor from Novartis Pharma (Basel, Switzerland), and 114 
IKK16, a selective inhibitor targeting both IKK1 and IKK2, from R&D Systems.  115 
Cell samples 116 
Peripheral blood cells from healthy volunteers were purchased from the French 117 
Blood Center (Toulouse, France) and CD19+CD27+ MBCs purified ( 95% purity) as 118 
described.10 When indicated, D10 early PCs (CD20-CD138+) were FACS-sorted 119 
using FITC-conjugated anti-CD20 mAb and PE- or APC-conjugated anti-CD138 120 
mAb. The purity of FACS-sorted cell populations was ≥ 95% as assayed by 121 
cytometry. Resto-6 stromal cells were used as a source of SCs. These SCs were 122 
obtained from a 15%/25% Percoll interface of dissociated human tonsil cells as 123 
previously described.25 Plastic-adherent cells were selected and expanded in RPMI 124 
1640 culture medium and 10% fetal calf serum (FCS) yielding to the Resto-6 SCs 125 
after 8 passages. Resto-6 SCs express usual mesenchymal stromal cell markers 126 
(CD90, CD73, and CD105) and can acquire properties of fibroblastic reticular cells 127 
(FRC) including expression of high levels of adhesion molecules and 128 
gp38/podoplanin, production of a dense meshwork of transglutaminase, and 129 
production of inflammatory and lymphoid chemokines upon stimulation by TNFα and 130 
Lymphotoxin-α1β2.25 Resto-6 SCs support efficiently the growth and survival of 131 
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normal B and T cells and of malignant lymphoma B cells, in particular after FRC-132 
commitment. They were used between passages 8 and 15. 133 
Cell cultures 134 
PCs were generated through a four-step culture. All cultures were performed in 135 
Iscove’s modified Dulbecco medium (IMDM, Invitrogen) and 10% FCS. In step 1, 136 
purified peripheral blood MBCs (1.5 x 105/ml) were activated for 4 days by CpG 137 
oligodeoxynucleotide and CD40 ligand (sCD40L) - 10 µg/ml of phosphorothioate 138 
CpG oligodeoxynucleotide 2006 (Sigma), 50 ng/ml histidine tagged sCD40L, and 139 
anti-poly-histidine mAb (5 µg/ml), (R&D Systems) - with IL-2 (20 U/ml), IL-10 (50 140 
ng/ml) and IL-15 (10 ng/ml) in 6 well culture plates. In step 2, PBs were generated by 141 
removing CpG oligonucleotides and sCD40L and changing the cytokine cocktail (IL-142 
2, 20 U/ml, IL-6, 50 ng/ml, IL-10, 50 ng/ml and IL-15, 10 ng/ml). In step 3, PBs were 143 
differentiated into early PCs adding IL-6 (50 ng/ml), IL-15 (10 ng/ml) and IFN-αҏҞ500 144 
U/ml) for 3 days. In step 4, early PCs were differentiated into LLPCs using either 145 
coculture with SCs, transwell culture, or a cytokine cocktail, and the cultures 146 
maintained for months. Confluent monolayers of SCs were generated in 6-, 24-, or 147 
48-well flat-bottom culture plates and PCs were then added onto the monolayers 148 
together with various cytokines. These cocultures of PCs and SCs could be 149 
maintained for months with the same SC monolayer, adding fresh culture medium 150 
and growth factors once by week. Cocultures of PCs and SCs without cell contact 151 
were done seeding SCs in the lower chamber of 6-well transwells and PCs in the 152 
upper compartment, both compartments being separated by a 0.4 µm-polycarbonate 153 
membrane (Corning, New-York, NY). SC-conditioned medium (SC-CM) was obtained 154 
by culturing confluent monolayers of SCs for 5 days with culture medium. The culture 155 
supernatant was 0.2 µM filtered and frozen and 50% of SC-CM was added to PC 156 
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cultures, and renewed every week. Finally, LLPCs were also obtained adding IL-6 157 
(10 ng/ml) and either APRIL (200 ng/ml) or BAFF (200 ng/ml). 158 
Assay for cell viability and cell growth 159 
Cell concentration and viability were assessed using trypan blue dye exclusion test. 160 
The number of metabolic active cells was also determined using intracellular ATP 161 
quantitation with a Cell Titer Glo Luminescent Assay (Promega Corporation, 162 
Madison, WI).  163 
Cell cycle analysis, immunophenotypic analysis, and cytology 164 
The cell cycle was assessed using DAPI staining (Sigma-Aldrich) and cells in the S 165 
phase using incubation with bromodeoxyuridine (BrdU) for 1 hour and labelling with 166 
an anti-BrdU antibody (APC BrdU flow kit, BD Biosciences) according to 167 
manufacturer’s instructions. Cells were stained with a combination of 4 to 7 mAbs 168 
conjugated to different fluorochromes. The Cytofix/Cytoperm kit (BD Biosciences) 169 
was used for intracellular staining of IgM, IgA, IgG or Ki67 antigen.10 Flow cytometry 170 
analysis was performed with a FACSAria cytometer using FACSDiva 6.1 (Becton 171 
Dickinson, San Jose, CA) and with a Cyan ADP cytometer driven by the Summit 172 
software (Beckman Coulter). Kaluza software (Beckman Coulter) was used for data 173 
analysis. The fluorescence intensity of the cell populations was quantified using the 174 
stain index (SI) formula: [mean fluorescence intensity (MFI) obtained from a given 175 
mAb minus MFI obtained with a control mAb]/[2 times the standard deviation of the 176 
MFI obtained with the same control mAb].10 Cytospin smears of cell-sorted CD20-177 
CD138+ D30 PCs were stained with May-Grünwald-Giemsa. 178 
Analysis of Ig secretion 179 
ELISA. Flow cytometry sorted PCs were cultured at 106 cells/ml for 24 hours and 180 
culture supernatants harvested. IgM, IgA, or IgG concentrations were assessed by 181 
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ELISA using human IgM, IgA, and IgG ELISA kits from Bethyl Laboratories 182 
(Montgomery, TX), according to the manufacturer's recommendations.  183 
ELISPOT. The number of IgM, IgA, or IgG secreting PCs was evaluated with the 184 
ELISPOT assay,26 seeding 500 PCs by well in ELISPOT plates and culturing cells  185 
for 18 hours. The number and size of IgM, IgA, and IgG elispots were assessed 186 
using the Biosys Bioreader 5000 apparatus (Biosys, Miami, FL). 187 
Microarray hybridization and bioinformatics analysis 188 
RNA was extracted and hybridized to human genome U133 Plus 2.0 GeneChip 189 
microarrays, according to the manufacturer’s instructions (Affymetrix, Santa Clara, 190 
CA). Gene expression data are deposited in the ArrayExpress public database 191 
(http://www.ebi.ac.uk/microarray-as/ae/). The accession numbers are E-MEXP-3034 192 
for prePBs, E-MEXP-2360 for PBs and BMPCs, E-MEXP-3945 for day 10 (D10) early 193 
PCs and D30 PCs, and E-MTAB-2118 for Resto-6 SCs. Gene expression data were 194 
analyzed with our bioinformatics platforms (RAGE, http://rage.montp.inserm.fr/)27 and 195 
Amazonia (http://amazonia.transcriptome.eu/).28 Genes differentially expressed 196 
between cell populations were determined with the SAM statistical microarray 197 
analysis software.29 The clustering was performed and visualized with the Cluster 198 
and TreeView softwares.30 Gene annotation and networks were generated with the 199 
Reactome Functional Interaction Cytoscape plugin (http://www.cytoscape.org/).  200 
Statistical analysis 201 
Statistical comparisons were made with the non-parametric Mann-Whitney test, 202 
unpaired or paired Student’s t-test using SPSS software. P-values ≤ .05 were 203 
considered as significant.204 
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RESULTS 205 
IL-6 in combination with APRIL or BAFF or APRIL/BAFF-unrelated stromal-cell 206 
soluble factors supports the generation and survival of PCs in vitro 207 
Starting from MBCs, early PCs can be generated within 10 days using a 3-step 208 
culture. These early PCs could survive poorly in presence of IL-6 (Figure 1A). Adding 209 
human tonsil SCs could promote PC survival with 28% surviving CD138 PCs at day 210 
30 (Figure 1A). In the presence of SCs, the CD138 fluorescence staining index at 211 
day 14 was increased 3 fold (P = .006) compared to day 14 PCs generated with IL-6 212 
alone (Figure 1B and 1C). It progressively increased 2 fold from day 14 to day 30 (P 213 
= .032) and then was stable up to day 60 (Figures 1B and 1C). Coculturing early PCs 214 
separated from SCs in transwell culture plates promoted PC survival at the same 215 
extent as coculture of PCs with SCs at day 14, 17, 24 and 30, showing a contact 216 
between PCs and SCs is not mandatory (Figure 2A). In agreement, coculture 217 
supernatant of PCs with SCs (PC/SC-CM) or of SCs alone (SC-CM) also promoted 218 
PC survival at day 30 (Figure 2A). Various growth recombinant factors - APRIL, 219 
BAFF, SDF-1, IGF-1 - known to sustain malignant PC survival19 did not induce PC 220 
survival when used alone (Figure 2B). IL-6 alone supported PC survival but at a 76% 221 
lower level than that induced by the SC-CM (P = .003). Adding APRIL together with 222 
IL-6 increased significantly 6.5 fold (P = .02) the IL-6 PC survival activity (Figure 2B). 223 
Adding BAFF also increased the PC survival induced by IL-6 (P = .02) and SDF-1 224 
and/or IGF-1 did not increase IL-6 activity (Figure 2B). The PC survival induced by 225 
the SC-CM was fully abrogated by an anti-IL-6 mAb showing the critical role of IL-6 226 
produced by SCs, but was unaffected by an APRIL/BAFF inhibitor, TACI-Fc (Figure 227 
2C). The TACI-Fc APRIL/BAFF inhibitor fully blocked the ability of APRIL to increase 228 
2.2 fold the PC generation induced by the SC-CM (Figure 2C). It also inhibited the 229 
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APRIL-induced growth of the XG1 myeloma cell line (supplementary Figure 1).31 As 230 
APRIL/BAFF activate NF-κB pathways,32 we investigated whether these pathways 231 
could be involved in PC generation by SCs. An inhibitor of both canonical and 232 
alternative NF-κB pathways (IKK16) did not affect the generation of PCs supported 233 
by SCs, whereas it impeded the additive effect of APRIL in PC generation promoted 234 
by SCs (Figure 3). Thus, SCs produce communication signals, which cooperate with 235 
IL-6 to promote PC survival and are not inhibited by a NF-κB inhibitor. This is in 236 
agreement with the low expression of NF-κB-induced genes33 in PCs generated with 237 
SCs in vitro contrarily to BMPCs (supplementary Figure 2). These communication 238 
signals are not SDF-1 or IGF-1 since the SC-CM activity was unaffected by their 239 
specific inhibitors (Figure 2C). Adding these 3 inhibitors together (APRIL/BAFF, SDF-240 
1 and IGF-1 inhibitors) yielded to an apparent decrease in SC-CM induced PC 241 
generation, which did not reach statistical significance (Figure 2C).  242 
Of note, PCs could survive up to 120 days in these culture conditions adding fresh IL-243 
6, APRIL and culture medium weekly and cultures were stopped after 120 days for 244 
convenience but not due to a decline in PC survival. These PCs were thus termed 245 
LLPCs. These results indicate that IL-6 is mandatory to induce the long-term survival 246 
of LLPCs in combination with either APRIL or BAFF or with APRIL/BAFF-unrelated 247 
soluble factors produced by SCs.  248 
Characterization of D30 PCs  249 
D30 PCs had a more mature PC phenotype than D10 early PCs with a progressive 250 
7.4-fold increase in CD138 density (Figure 1C, P  .001), a 2.2-fold increase in CD54 251 
staining index, a 1.5-fold increase in CD9+ PCs, and a decrease in HLA-DR, CD45, 252 
CD62L, CCR10 expressing PCs and staining indexes (P  .05, Figure 4 and 253 
supplementary Figure 3). D30 PCs did not proliferate (0.04% cells incorporating 254 
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BrdU), whereas a low fraction of D10 early PCs was in the S phase of the cell cycle 255 
(4% BrdU+) (Figure 5A and 5B). D30 PCs displayed the cytology of mature PCs and 256 
produced cytoplasmic kappa or lambda Ig light chains (supplementary Figure 4). Day 257 
60 PCs comprise IgG PCs only, with a quick disappearance of IgM PCs (no more 258 
detectable at day 30) and a progressive one of IgA PCs as assayed by FACS, ELISA 259 
and ELISPOT assays (Figures 6 A-F). Of note, the rate of IgG production was similar 260 
between day 30 and day 60 PCs (Figure 6F). The number of IgG and IgM producing 261 
cells and the Ig isotype produced were not significantly different starting from the 262 
same number of LLPCs generated with either SC coculture, IL-6+APRIL, SC-CM or 263 
APRIL+SC-CM (Figure 6G). There was a trend in increasing IgA secreting cells in the 264 
two experiments adding APRIL compared to the culture groups without APRIL (P < 265 
.1). Combining data of these two experiments show APRIL increased 3.4 fold the 266 
number of IgA secreting cells (47 vs. 14 IgA secreting cells/500 PCs, P < .001, Figure 267 
6G). 268 
B and PC transcription factors 269 
D30 PCs had a higher expression of genes coding for IRF4 and BLIMP1 PC 270 
transcription factors than D10 early PCs and failed to express PAX5 (P  .02, Figure 271 
7). D30 PCs expressed 3-fold more the spliced form of XBP1 mRNA than D10 early 272 
PCs and 2-fold more the unspliced mRNA form than early PCs, resulting in an 273 
increased XBP1s/XBP1u mRNA ratio (P  .009, Figure 7). Of note, BCL6 gene 274 
expression in D30 PCs was low compared to that in B lymphocytes but significantly 275 
higher than that in early PCs (P = .04, Figure 7). 276 
Gene expression profile (GEP) of D30 PCs  277 
In vitro generated D4 prePBs, D7 PBs, D10 early PCs, D30 PCs, and BMPCs 278 
purified from healthy individuals were profiled using Affymetrix U133 plus 2.0 279 
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microarrays. D30 PCs were generated using cocultures with SCs. The 5 populations 280 
are classified into 2 major clusters, a PC cluster comprising D10 early PCs, D30 PCs, 281 
and BMPCs and a PB cluster comprising prePBs and PBs (Figure 8). To look for 282 
genes indicator of LLPCs, we ran a SAM supervised analysis comparing D10 early 283 
PCs to D30PCs+BMPCs starting from the 5000 genes with the highest variance. 160 284 
probe sets (141 unique genes) were overexpressed in D30PCs+BMPCs compared to 285 
D10 early PCs (Wilcoxon statistic, fold change  2, FDR  1%) and 490 (427 unique 286 
genes) in D10 early PCs versus D30PCs+BMPCs (supplementary Table 1). Genes 287 
coding for translation, focal adhesion, IL-6 signalling, and integrin signalling pathways 288 
were enriched in D30PC+BMPC genes (supplementary Table 2), and genes coding 289 
for DNA replication and mitosis in D10 early PCs (supplementary Table 3). The gene 290 
expression profiles of LLPCs harvested from the spleen of patients with primary 291 
immune thrombocytopenia treated with rituximab anti-CD20 mAb was recently 292 
documented and compared to that of PBs harvested from the spleen of untreated 293 
patients.34 Similarly to the current in vitro generated LLPCs, LLPCs from these 294 
patients overexpress genes coding for PC transcription factors (JUN, FOS, EGR1), 295 
negative regulators of the cell cycle (KLF4, KLF2, PPP1R15A) and cell 296 
surface/cytokine receptors (CD9, SDC1, FCRL5). Conversely, similarly to in vitro-297 
generated D10 early PCs, patients’ PBs overexpress genes coding for positive cell 298 
cycle regulators (CCND2, BUB1B, BUB1, TIMELESS, CENPF, MAD2L1, BIRC5, 299 
ZWINT, MKI67, MCM4, CCNB2) and surface/cytokine receptors (ITGB1, TNFSF10) 300 
(supplementary Table 1). Comparing gene expression between BMPCs and D30 301 
PCs, 198 unique genes were overexpressed in BMPCs and 555 in D30 PCs (SAM 302 
supervised analysis, Wilcoxon statistic, fold change  2, FDR  1%, supplementary 303 
Table 4). Genes coding for protein metabolism, translation, antigen processing and 304 
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presentation, and CXCR4 signalling were enriched in BMPC genes (supplementary 305 
Table 5). Genes coding for glypican pathway, TGFβ receptor and Smad2/3 306 
signalling, protein export and proteasome were enriched in D30 PC genes  307 
(supplementary Table 6). GEP were done using D30 PCs generated with SCs and 308 
IL-6. It could be of interest to investigate further whether adding APRIL together with 309 
IL-6 or SC-CM could change the gene expression profiling, making it closer to that of 310 
BMPCs.  311 
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DISCUSSION 312 
This study shows i) the feasibility to generate human mature PCs in vitro, ii) the long-313 
term survival of these PCs does not require a contact with niche cells, but only cell 314 
communication factors, in particular IL-6 and APRIL. 315 
These PCs are called long-lived PCs because they are non-cycling PCs surviving 316 
and producing Igs for months in vitro as their counterpart in vivo.1,35,36 In addition, 317 
they have a phenotype similar to that of LLPCs in vivo: high expression of CD138, 318 
increased expression of CD9, weak expression of CD62L, CD45 and HLA-DR 319 
compared to PBs and early PCs.22,37 These in vitro generated LLPCs expressed 320 
IRF4 and PRDM1 genes coding for PC transcription factors at a higher level than 321 
early PCs. Murine LLPCs also highly express Blimp1 compared to early PCs in the 322 
BM.38 XBP1 is a master regulator of unfold protein response critical to protect PCs 323 
from stress induced by high Ig production.39 XBP1 mRNA has to be spliced to 324 
encode for an active protein and, in agreement, we found that LLPCs had an 325 
increased ratio of spliced to unspliced XBP1 mRNAs compared to early PCs. LLPCs 326 
expressed weakly but significantly BCL6 gene compared to early PCs. This deserves 327 
further study since Bcl6 is also inducible in malignant PCs in response to SC-derived 328 
factors, conferring a survival advantage on them.2  329 
A second major finding is that the generation and survival of human LLPCs do not 330 
require a contact with niche cells in vitro, but can be obtained with 2 recombinant 331 
growth factors only, IL-6 and APRIL. APRIL can be replaced by BAFF, which 332 
activates the same receptors. In addition, APRIL can be replaced by APRIL/BAFF-333 
unrelated soluble factors produced by SCs. Of note, an inhibitor of both the canonical 334 
and alternative NF-κB pathways did not affect the generation of LLPCs supported by 335 
SCs, whereas it abrogated the additive effect of APRIL in getting LLPCs with SCs. In 336 
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addition, a set of genes, whose expression is induced by NF-κB pathway activation in 337 
malignant PCs,33 is poorly expressed in LLPCs generated with SCs in vitro compared 338 
to BMPCs as previously mentioned by Cocco et al.24 Thus the activation of the NF-339 
κB pathway is not mandatory to generate LLPCs in vitro, but could enhance it. The 340 
current data are in line with recent findings showing that a combination of APRIL, 341 
BAFF, IGF-1, SDF-1 and VEGF can support modestly the in vitro 14-day survival of 342 
human PCs harvested from the BM, whereas STAT3 activating cytokines, in 343 
particular IL-6, are critical.40 344 
Using more complex culture conditions, including IL-6, IL-21, IFN-α and SC-CM, a 345 
recent study has shown human LLPCs can be generated in vitro also.24 That the in 346 
vitro long-term survival of human PCs can be supported by 2 growth factors (IL-6 and 347 
APRIL) only is quite surprising regarding the current view of the complexity of the PC 348 
niche, comprising SCs and various hematopoietic cells (eosinophils, dendritic cells, 349 
megakaryocytes, neutrophils, basophils).6,14,41 SCs are thought to serve as docking 350 
cells bringing close together PCs and hematopoietic cells,14 but also producing 351 
soluble factors promoting PC survival, in particular IL-6 and galectin.42,43 The ability 352 
of hematopoietic cells to sustain PC survival is due mainly by their ability to produce 353 
APRIL.9,11  354 
The fact that soluble growth factors can replace niche cells for the generation and 355 
survival of LLPCs in vitro suggests it could be the case in vivo and questions about 356 
the regulation of LLPC count in vivo. It is generally assumed that the tiny PC count in 357 
the BM is regulated by the rarity of BM niche cells5, new PCs being in competition 358 
with old ones for the availability of niche cells.44 The current finding suggests the PC 359 
niche is mainly a liquid niche comprising a life-sustaining mixture and concentration 360 
of chemokines and growth factors, which is likely the case close to the docking SCs 361 
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attracting both PCs and hematopoietic cells.14 When entering the BM, if a PC cannot 362 
migrate close to a SC, it will not encounter the life-sustaining concentrations of 363 
soluble factors and die. But in case of deregulated production of these cell 364 
communication signals such as in inflammatory conditions, one can expect many 365 
PCs may survive in vivo. This may explain the accumulation of LLPCs in the spleen 366 
of patients with primary immune thrombocytopenia treated with Rituximab anti-CD20 367 
mAb, in association with a 2-fold increase in BAFF concentration in the spleen 368 
compared to Rituximab untreated patients.34 Besides genomic abnormalities, this 369 
could also explain the progressive accumulation of premalignant PCs and then 370 
malignant PCs in patients with malignant PC disorders who display increased plasma 371 
concentrations of IL-6,45 APRIL or BAFF.46 372 
The current finding of a mandatory role of IL-6 to promote the survival of human 373 
LLPCs in vitro questions the role of IL-6 for LLPC maintenance. In mice, whereas IL-374 
6 produced by SCs is mandatory to get the survival of BMPCs in vitro,16,17 the 375 
survival of transferred LLPCs is not impaired in IL-6-/- mice unlike APRIL-/- ones.14 376 
This is likely due to bias in the murine or human models used. In particular, whereas 377 
LLPCs can not be transferred in APRIL-/- mice14, Ag-specific PCs can be generated in 378 
APRIL-/- mice using repeated Ag boosts indicating additional factors can replace 379 
APRIL.14 In IL-6-/- mice, a role of the other cytokines able to trigger gp130 IL-6 380 
transducer chain and/or STAT3 activation and to supplement for a deficit in IL-6 381 
induced signalling to support PC survival has not been evaluated. This is the case in 382 
humans since a recent study has emphasized that inhibition of STAT3 activation by 383 
small compounds can fully block the in vitro 14-day survival of human PCs harvested 384 
from the peripheral blood or BM of healthy individuals. STAT3 activation in these PCs 385 
could be driven by either IL-6, IL-10 or IL-21.40  386 
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These in vitro models to get human PCs likely introduce some bias, in particular by 387 
the method to activate B cells (through BCR, CD40, or TLR), the combination of 388 
cytokines used to generate prePBs, PBs, early PCs and then LLPCs, the origin of 389 
stromal cells and the culture conditions influencing PC metabolism (nutrients, 390 
glucose, O2 concentration).
10,21,24,26 In the current model, we used a stromal cell line 391 
obtained from tonsils because it grow easily until confluence and at confluence, can 392 
survive for several months without proliferating but providing a continuous SC 393 
support. In initial experiments, similar data were obtained in term of phenotype and 394 
long-term survival with BM SCs. But it is of major interest to investigate further 395 
whether the use of SCs from different tissue origins could change the phenotype and 396 
gene expression profiling of LLPCs, in particular their proximity with BMPCs. For 397 
example, a progressive loss of IgA secreting PCs occurred in cultures with tonsil SCs 398 
or SC-CM likely due to the lack of a critical survival factor for IgA PC survival in vitro. 399 
Adding APRIL can revert this loss, increasing 3.4 fold the survival of IgA secreting 400 
PCs and this could eventually also occur with BM SCs. The ease of the current 401 
model to get PCs in vitro will make possible further identification of these possible 402 
biases.  403 
All prePBs and PBs generated in this model express CD19 whereas Chaidos et al.47 404 
reported recently the existence of CD19-CD38+CD138- plasmablasts (called Pre-405 
PCs) in healthy individuals, together with the known CD19+CD38+CD138- PBs and 406 
CD19+CD38+CD138+ PCs.22 The malignant counterpart of these Pre-PCs are found 407 
in patients with MM. Running a supervised analysis of gene expression profiling of 408 
malignant Pre-PCs and PCs, Chaidos et al. found enrichment of genes coding for 409 
epigenetic pathways.47 The in vitro model we used likely failed to generate these 410 
CD19-CD38+CD138- since all prePBs generated at day 4, PBs at day 7 and PCs at 411 
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day 10 express CD19.10,26 In addition, the epigenetic genes differentially expressed 412 
between malignant Pre-PCs and PCs could not classify the current in vitro generated 413 
PBs, early PCs and LLPCs (data not shown). 414 
Besides its interest for understanding the fine pathways controlling PC generation 415 
and survival in humans, the current model should be promising to study the 416 
mechanisms involved in malignant PC disorders and controlling the activity of drugs 417 
used to treat patients with these disorders. As several genes whose expression or 418 
abnormalities are associated with disease activity have been identified,48-55 their 419 
modulation throughout the different stages of PC generation (prePBs, PBs, early 420 
PCs, LLPCs) could help to understand better their function. Of note, it is now feasible 421 
to force or repress the expression of a given gene in these PCs using measles 422 
envelop pseudotyped lentiviral delivery.56 The same holds true for drugs used to treat 423 
patients with MM, in particular to identify if these drugs could target a specific PB or 424 
PC stage and the underlying mechanism.  425 
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FIGURE LEGENDS 626 
Figure 1. Generation and survival of mature CD138bright PCs in vitro. 627 
(A) PCs (CD38+CD138+ cells) were generated with or without stromal cells (SCs) in 628 
the presence of IL-6 (10 ng/ml) and cell count and viability assayed at day (D) 10, 14, 629 
24, 30, and 60 using trypan blue dye exclusion. Data are the mean concentration of 630 
viable cells ± SD determined in six separate experiments. *The mean value is 631 
significantly higher than that in culture without SCs at the same culture day using a 632 
paired t-test (P  .05). (B) Expression of CD138. The histograms show FACS 633 
labelling with an anti-CD138 (black) or an isotype-matched control mAb (white) of 634 
one experiment representative of four. The percentages of CD138 positive cells and 635 
CD138 staining index (SI) are indicated in the panels. (C) CD138 fluorescence 636 
staining index. Data are the mean CD138 staining index ± SD of four separate 637 
experiments. Statistical analysis was done using a paired t-test. ns = not significant.  638 
Figure 2. IL-6 in combination with APRIL or BAFF or SC-CM supports the 639 
generation and survival of PCs in vitro. 640 
(A) D10 early PCs were FACS sorted and cultured from D10 to D30 either in contact 641 
with SCs (culture with SCs), or with SCs placed in a lower chamber of a transwell 642 
culture plate (SCs+PCs in transwells), or with supernatant of PC and SC coculture 643 
(PC/SC-CM), or culture supernatant of SCs (SC-CM). Results are the mean of viable 644 
cell counts ± SD of 3-paired experiments. ns: the mean count of PCs at a given 645 
culture day is not significantly different from that in the SC group at the same culture 646 
day using a paired t-test (B) FACS-sorted early PCs were cultured from D10 to D30 647 
with culture medium and 10% FCS (Co) or in the presence of recombinant cytokines 648 
and/or the SC-CM. The concentrations of cytokines used were 10 ng/ml for IL-6 and 649 
IGF-1 and 200 ng/ml for APRIL, BAFF, and SDF-1. Counts of metabolic active cells 650 
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were assayed quantifying intracellular ATP amount with a Cell Titer Glo Luminescent 651 
Assay. Results are the mean ± SD of the luminescent signals expressed as the 652 
percentage of that in the group cultured with the SC-CM, determined in 3- to 7-paired 653 
experiments. *The mean value is significantly different from that in the SC-CM group 654 
using a paired t-test. **The mean value is significantly different from that in the IL-6 655 
group using a paired t-test (P  .05). (C) Effect of various inhibitors of cytokines on 656 
the generation of plasma cells induced by the SC-CM. The anti-IL-6 mAb was used 657 
at a concentration of 10 µg/ml, the TACI-Fc at 10 µg/ml, the AMD3100 (SDF-1 658 
inhibitor) at 10 µM and the IGF-1R inhibitor (NVP-AEW541) at 1 µM. Metabolic active 659 
cells were assayed quantifying intracellular ATP amount with a Cell Titer Glo 660 
Luminescent Assay. Results are the mean ± SD of the luminescent signals 661 
expressed as the percentage of that in the group cultured with the SC-CM, 662 
determined in 3- to 10-paired experiments. *The mean value is significantly different 663 
from that in the SC-CM group using a paired t-test.  664 
Figure 3. A NF-κB inhibitor does not affect the generation of PCs by SCs but 665 
inhibited the additive effect of APRIL. 666 
PCs were generated with SCs only or with SCs and 200 ng/ml recombinant APRIL. 667 
The IKK16 NF-κB inhibitor (1 or 3 µM) was added for 4 days in 2 culture groups and 668 
PCs counted at the end of the culture. For each experiment the PC count was 669 
expressed as the percentage of the PC count obtained with the control group of the 670 
same experiment (SCs or SCs + APRIL). Results are the mean percentages ± SD of 671 
five separate experiments. *The mean percentage is significantly decreased 672 
compared to that in the SCs + APRIL group using a paired t-test. 673 
Figure 4. D30 PCs have a more mature phenotype than D10 early PCs. 674 
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PC phenotype was assessed by flow cytometry. Results are the mean percentage ± 675 
SD of positive cells and the mean staining index ± SD determined in 4 to 6 separate 676 
experiments. *The mean value is significantly different from that in D10 PCs using a 677 
paired t-test (P  .05). 678 
Figure 5. D30 PCs do not cell cycle. 679 
The cell cycle was assessed using DAPI staining and quantification of cells in the S 680 
phase using bromodeoxyuridine (BrdU) incorporation and labelling with an anti-BrdU 681 
antibody. (A) Dot plots show a representative experiment out of three. The 682 
percentages of cells in the G0/G1, S, and G2/M phases are indicated. (B) Results are 683 
the mean percentage ± SD of cells in the S phase of three separate experiments. 684 
Figure 6. D30 and D60 PCs are functional PCs that produce Igs continuously. 685 
FACS-sorted D10 early PCs were cultured with SCs (A-F) or growth factors as 686 
indicated (G). (A-C) Cytoplasmic (cy) Igs (IgG, IgA, and IgM) (A), cy-light chains (B), 687 
and surface (s) Igs (C) were assessed by flow cytometry. Results are the mean 688 
percentage ± SD of positive cells from 5 separate experiments. (D) IgG, IgA, and IgM 689 
production was assessed by ELISA. Results are the mean ± SD of Ig production in 690 
pg per cell and per day determined in 3 separate experiments. (E) The number of 691 
IgG-, IgA-, and IgM-secreting cells was assessed by ELISPOT. Results are the mean 692 
Ig-secreting cell number ± SD from 4 separate experiments. (F) ELISPOTs from a 693 
representative experiment are shown. (G) FACS sorted D10 early PCs were cultured 694 
with SCs or with a combination of cytokines and/or SC-CM as indicated. The number 695 
of Ig-secreting cells was determined by ELISPOT at D30 of culture. Results are the 696 
mean Ig-secreting cell number ± SD from 3 separate experiments. *The mean value 697 
is significantly different from that in D10 PCs using a paired t-test. 698 
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Figure 7. Gene expression of transcription factors involved in PC 699 
differentiation. 700 
Naive B cells (BCs), D10 early PCs, and D30 PCs were FACS sorted. Gene 701 
expression of IRF4, PRDM1, XBP1u, XBP1s, PAX5, and BCL6 assayed by real-time 702 
RT-PCR. The mRNA level in the different cell populations was compared assigning 703 
the arbitrary value 1 to gene expression in BCs. Data are the mean value ± SD of 704 
gene expression determined in 5 separate experiments. The ratio XBP1s/XBP1u in 705 
D10 early PCs and D30 PCs is shown. *The mean value is significantly different from 706 
that in D10 PCs using a paired t-test (P  .05). 707 
Figure 8. Unsupervised clustering of gene expression profile of purified D4 708 
prePBs, D7 PBs, D10 early PCs, D30 PCs, and BMPCs. 709 
D4 prePBs, D7 PBs, D10 early PCs, D30 PCs and BMPCs were profiled using 710 
Affymetrix U133 plus 2.0 microarray and an unsupervised hierarchical clustering was 711 
run with the 5000 probe sets with the highest variance (log transform, center genes 712 
and arrays, uncentered correlation and average linkage). The 5 populations are 713 
classified into 2 major clusters, a PC cluster comprising D10 early PCs, D30 PCs and 714 
BMPCs (r = 0.11) and a plasmablast cluster comprising prePBs and PBs (r = 0.20). 715 
The horizontal lines represent the normalized and centered expression of each of the 716 
5000 genes in the samples and are depicted according to the color scale shown at 717 
the bottom (-1.5 to 1.5 on a log base 2 scale).  718 
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